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Abstract
Problem: Selecting appropriate medications for the aging population is challenging
considering the number of chronic illnesses, prescriptions, and healthcare providers
involved in their care, not to mention age related changes that impact pharmacokinetics.
Significance: Inappropriate medications in geriatric patients can lead to adverse drug
reactions (ADR). Medication review tools can assist in the identification of potentially
inappropriate medications (PIM) to avoid or closely monitor and prevent ADRs.
Purpose: Describe and compare the application of select sections of the STOPP
(Screening Tool of Older Persons Prescriptions) /START (Screening Tool to Alert to
Right Treatment) and Beers Criteria in a geriatric population. Specific aims include
describing and comparing: 1) the rate of PIM identified by sections of the Beers and
STOPP Criteria, 2) the rate of potential prescription omissions (PPO) identified by a
section of the START Criteria, 3) the most common PIM or PPO drug classes identified,
4) those with polypharmacy (>5 medications), and 5) the time for criteria application.
Design: Retrospective descriptive, comparative chart review.
Results: A total of 468 medications were prescribed, an average of 7.43 per patient, with
73.02% of patients with polypharmacy.

Beers Criteria identified 32 PIM in 39.7% while

STOPP Criteria identified 67 PIM in 58.7%. There was a high statistical difference
between the number of PIM identified by the STOPP Criteria compared to the Beers
Criteria (P=0.01). A total of 16 PPO were identified with START Criteria in 17.5%.
Keywords: potentially inappropriate medication, potential prescription omissions,
STOPP/START Criteria, Beers Criteria, adverse drug reactions
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Chapter One: Introduction
Introduction
In the United States (U.S.) the geriatric population, individuals 65 years and older,
is growing (Patterson, Hughes, Kerse, Cardwell, Bradley, 2012; Hajjar, Cafiero, Hanlon,
2007). According to the 2010 census, 40 million Americans are 65 years of age and
older. It is estimated the geriatric population will increase to 72 million or 20 percent of
the national population by 2030 as the baby boomer generation reaches advanced age
(Federal Interagency Forum on Aging, 2010). Advanced age is associated with multiple
normal aging changes. These changes coupled with increased numbers of chronic
diseases, increased numbers of healthcare providers, and multiple medications increase
the complexity of the plan of care (Opondo, Eslami ,Visscher, Rooij, Verheij, Korevaar,
Abu-Hanna, 2012; Cahir, Fahey, Teeling, Teljeur, Feely, Bennett, 2010; Ramaswamy,
Maio, Diamon, Talati, Hartmann, Arenson, Roehl, 2010).
Forty percent of geriatric patients are currently taking five or more medications to
treat their chronic diseases, placing them at a higher risk for potentially inappropriate
medications (PIM), leading to possible adverse drug reactions (ADR) (Therapeutic
Research Center, 2011; Pham & Dickman, 2007). The most common ADRs include
falls, fractures, and delirium which can impact functional ability and quality of life (Pham
& Dickman, 2007). For these reasons, the problem of PIM is a growing concern among
providers who prescribe medications for the geriatric population.
Utilizing a medication screening tool in outpatient settings within the U.S. may be
an effective method for preventing PIM and decreasing potential for ADR in geriatric
patients. Medication screening tools are not meant to replace clinical judgement, but
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rather to encourage closer monitoring or use of certain medications that could be
potentially inappropriate or lead to ADR (Cahir et al, 2010). The American Geriatric
Society recommends the use of the Beers Criteria while the European Union Geriatric
Medicine Society recommends the STOPP (Screening Tool of Older Persons’
Prescriptions)/START (Screening Tool to Alert doctors to Right Treatment) Criteria as a
medication screening tool (Fick & Semla, 2012; Marcum & Hanlon, 2012). Both criteria
are explicit screening tools created by expert consensus panels that may be generalizable
to the geriatric population (Cahir et al, 2010).
The Beers Criteria is organized into lists of medications to avoid or use with
caution while the STOPP/START Criteria is organized by body system into lists of
medication recommendations to either discontinue or initiate (American Geriatric
Society, 2012; Gallagher, Ryan, Byrne, Kennedy, O’Mahony, 2007). Considering the
most common ADRs of falls and fractures, and the high number of geriatric patients
suffering from musculoskeletal conditions, including osteoarthritis (OA) and osteoporosis
(OP,) the Beers and STOPP Criteria have sections that may be useful to identify PIM and
the START to identify potential prescription omissions (PPOs) associated with these
common conditions. Both criteria were reviewed in their entirety to ensure similar
sections had been chosen from each criteria. These sections include the 1) Beers history
of falls and fracture section, 2) Beers pain medication section, 3) Beers history of gastric
ulcers, 4) Beers history of chronic kidney disease, 5) STOPP central nervous system and
psychotropic drugs section, 6) STOPP musculoskeletal drugs section, 7) STOPP drugs
that adversely affect those prone to falls section, 8) STOPP analgesic drugs, and 9)
START musculoskeletal drug sections. The Beers Criteria sections three and four were
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selected due to their similarity with the STOPP/START Criteria's musculoskeletal
sections (sections six and nine). The STOPP Criteria section five was selected because of
its similarity with the Beers history of falls and fractures section (section one). Pain
medication sections from each criteria were included because of the high risk for falls,
confusion, and delirium in geriatric patients related to these medications.
Therefore, the purpose of this retrospective study was to describe and compare the
application of select sections of the STOPP/START and Beers Criteria in a geriatric
population in a musculoskeletal specialty setting in the United States. The aims of the
present study were to describe and compare: 1) the rate of PIM identified by specific
sections of the Beers Criteria (Appendix B) and specific sections of the STOPP Criteria
(Appendix A), 2) the rate of PPO identified by a specific section of the START Criteria
(Appendix A), 3) the most common PIM or PPO drug classes identified by each criteria;
4) identify those with polypharmacy (greater than 5 medications, and 5) the length of
time for application of each criteria.
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Chapter Two: Literature Review & Theoretical Framework
Literature Review
Americans, age 65 years and older, increased by 15.3 percent between the years
2000 and 2010. Now one in every eight people is over 65 years of age (Administration
on Aging U.S. Department of Health and Human Services, 2011). Individuals over 65
years of age experience multiple normal aging changes and an increased chronic disease
burden. Over two thirds of Medicare beneficiaries have two or more chronic diseases
and 14 percent have six or more (Centers for Medicare & Medicaid Services, 2012). In
2007, geriatric patients went to a healthcare provider seven times more often than
younger patients and were three times more likely to be admitted to the hospital
(Administration on Aging U.S. Department of Health and Human Services, 2011).
Fall induced osteoporotic fractures are the leading cause of hospitalization in geriatric
patients and falls are their leading cause of injury related death (CDC, 2012; Dalleur,
Sinewine, Henrared, Losseau, Speybroeck, Boland, 2012). One in three geriatric
patients, 65 years and older, fall each year (Kojima, Akishit, Nakamaura, Nomaura,
Ogawa, Iijima, Eto, Ouchi, 2010; Ziere, Dieleman, Hofman, Pols, Van der Cammen,
Stricker, 2005; Hegeman, van den Bemt, Duysens, Limbeek, 2009). The cost for
treatment of falls in the U.S. was $30 billion in 2010 (CDC, 2012).
Several normal aging changes and chronic diseases may increase the risk of falls
and consequently a serious injury, including fractures (Gallagher et al, 2007). Some of
these normal aging changes include hearing impairment, changes in vision, diminished
coordination and reflexes, and decreased bone density (American Psychology
Association, 1998; Whitaker, 2011; Klotz, 2009; Clyne, Bradley, Smith, Hughes,
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Motterlini, Clear, McDonnell, Williams, and Fahey, 2013). The most common chronic
diseases that affect the musculoskeletal system are arthritis and osteoporosis (OP)
(Kiebazk, 2002; Trivedi, Doll, Knaw, 2003). Arthritis affects half of all geriatric
patients, 75 years and older, and they often experience significantly decreased functional
ability and quality of life as a result of their disease (CDC, 2010). Osteoporosis affects 52
million men and women in the U.S. and decreased bone density predisposes these men
and women to fractures (Whitaker, 2011). One in three women and one in five men, age
50 and older, will at some point suffer a fracture as a result of OP (International
Osteoporosis Foundation, 2013).
A normal aging change in pharmacokinetics also increases the risk of falls
through increased likelihood of ADR (American Psychology Association, 1998;
Hamilton, Gallagher, Ryan, Byrne, O'Mahony, 2011). Pharmacokinetics involves the
effect the body has on medications including absorption, distribution, metabolism, and
excretion (Brouwer & Olney, 2004; Shahezwan, Wahab, Nyfort-Hansen, Kowalski,
2012). Absorption of medications becomes slowed with advancing age. Distribution of
medications is affected by sarcopenia. Sarcopenia is the normal, age related loss of
muscle mass and strength and is one of the biggest indicators of functional ability
(Brouwer & Olney, 2004). Metabolism and excretion of medications is affected by the
normal, age related decrease in renal and hepatic function (Williams, 2002).
Healthcare providers often struggle to find a balance between over prescribing
and under prescribing medications to treat or prevent disease in geriatric patients,
especially because chronic diseases often require more than one medication for treatment
(Patterson et al, 2012; Klotz, 2009; Williams, 2002). In the U.S., prevention and
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treatment of disease are often achieved with pharmaceuticals, but with more medications
comes the increased likelihood of an ADR (Werder & Preskorn, 2003; Perry 2008). The
U.S. General Accounting Office (1995) concluded that although, at that time, the geriatric
population made up only about 15 percent of the U.S. population, they accounted for the
purchase of 33 percent of prescription medications and 40 percent of over the counter
medications.
The most commonly used over the counter mediations among geriatric patients,
often used to treat OA are non-steroidal anti-inflammatory drugs (NSAIDs) (Page, 2000;
Ejaz, Bhojani, Joshi, 2004; Yayla et al, 2013; Pretorius, Gataric, Swedlund, Miller, 2013;
Berryman, Jennings, Ragsdale, Lofton, Huff, & Rooker, 2012). NSAIDs increase
systemic vascular resistance and can cause impaired renal perfusion leading to
hypertension, congestive heart failure development or exacerbations, and kidney
dysfunction (Page, 2000; Ejaz et al, 2004). The use of NSAIDs is associated with an
increased risk for gastrointestinal issues possibly leading to ulcers or bleeding, and
central nervous system problems possibly leading to falls (Hegeman et al, 2009; Yayla et
al, 2013).
Some of the other most common PIMs used in geriatric patients are long-term
opiates, benzodiazepines, and antihistamines (Shahezwan et al, 2012; Beers, Ouslander,
Rollingher, Reuben, Brooks, Beck, 1991; Beers, 1997; Fick, Cooper, Wade, Waller,
Maclean, Beers, 2003; Ryan, O’Mahony, O’Donovan, O’Grady, Weedle, Kennedy,
Byrne, 2012; American Pharmacists Association, 2012). These medications can cause
drowsiness, confusion, hypotension, bradycardia, and muscle weakness, increasing the
risk of falls (Shahezwan et al, 2012). Additionally, antihistamines can cause agitation,
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hallucinations, delirium, and can contribute to cardiovascular disorders including
dysrhythmias, prolonged QT intervals and postural hypotension in patients 65 years of
age and older (American Pharmacists Association, 2012; Coggins, 2013).
For the reasons previously discussed, geriatric patients are more susceptible to
PIM possibly leading to an ADR than younger patients (Gallagher et al, 2007;
Shahezwan et al, 2012). Geriatric patients with polypharmacy, more than five daily
medications, have a one in three chance of experiencing an ADR as a result of an
inappropriate medication and two thirds of those patients will need to seek medical care
for that reaction. Adverse drug reactions lead to increased healthcare utilization and cost
(Gallagher et al, 2007). In 2007, 12.9 million geriatric patients had at least one
hospitalization as a result of an ADR lasting three to six days (Administration on Aging
U.S. Department of Health and Human Services, 2011). Ninety five percent of those
ADRs are predictable and 28 percent are preventable (Pham & Dickman, 2007). The
most common ADR include falls, hip fractures, delirium, and urticaria all possibly
leading to increased healthcare costs, decreased functional ability, and decreased quality
of life (Pham & Dickman, 2007).
Consideration of the normal physiologic changes of aging, recalling knowledge of
pharmacology and realizing the possibility for patient harm could be helpful in
preventing PIM. Inappropriate medications may also be prevented with regular
medication reviews using a screening tool for guidance. Medication reviews are
recommended whenever a patient is seen for the first time, every six to 12 months, and
whenever a new medication is being considered or prescribed (Pham & Dickman, 2007;
Ryan, 2012). Medication reviews may be helpful in promoting the aggressive treatment
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of disease and minimizing the potential for ADR (Cahir et al, 2010; Steinman, 2007).
There are two different kinds of medication review processes including implicit
measures and explicit measures. Implicit measures allow providers to use their clinical
judgement to determine what is appropriate for each patient on an individual basis.
Explicit measures are based on guidelines and criteria developed by expert panels and
consensus opinion that should be generalizable to all patients in all situations (Cahir et al,
2010). There are several explicit screening tools available for providers to utilize when
conducting a medication review or considering prescribing a new medication for a
geriatric patient.
Beers Criteria
The most popular explicit medication screening tool used in the U.S. and
currently recommended by the American Geriatrics Society, National Committee for
Quality Assurance, Pharmacy Quality Alliance, and Centers for Medicare and Medicaid
Services is the Beers Criteria developed by Mark Beers M.D. and an expert consensus
panel in 1991 and updated in 1997, 2003, and 2012 (Cahir et al, 2010; O’Mahony,
Gallagher, Byrne, Hamilton, Barry, O’Connor, Kennedy, 2010; Vishwas, Harugeri,
Parthasarathi, Ramesh, 2012; Ryan, O’Mahony, Kennedy, Weedle, Byrne, 2009; Pham &
Dickman, 2007; Shahezwan et al, 2012; Ramaswamy et al, 2010; Fick & Semla, 2012;
Resnick & Pacala, 2012; Cherubini, Corsonello, Lattanzio, 2012; Vieira de Lima, Garbin,
Garbin, Sumida, Saliba, 2013; Gillespie, Alassaad, Hammarlund-Udenaes, Morlin,
Henrohn, Bertilsson, Melhus, 2013). The American Geriatric Society recommends that
the Beers Criteria will be updated every three years to remain current (Marcum &
Hanlon, 2012; Campanelli, 2012). The 2012 updated Beers Criteria is made up of 53
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medications divided into three sections including 1) PIM and classes to avoid in geriatric
patients independent of diagnosis, 2) PIM and classes to avoid considering certain disease
processes in geriatric patients, and 3) medications to use with caution in geriatric patients
(American Geriatric Society, 2012).
In 2012, an expert consensus panel updated Beers Criteria by removing
medications no longer available, adding medications new to the market since 2003,
updating the list of common geriatric diseases, adding a list of medications to use with
caution, and adding new research (Gallagher et al, 2007; Ryan et al, 2009; Pham &
Dickman, 2007; Fick & Semla, 2012; Resnick & Pacala, 2012). With the addition of
new research, a rating of the quality and strength of the evidence and recommendation is
given for each medication, regardless of whether it is classified by drug category or
disease process (American Geriatric Society, 2012; Resnick & Pacala). The expert
consensus panel emphasizes the Beers Criteria should never replace clinical judgement,
but rather serve as a reminder to closely monitor or avoid, if possible, certain medications
in the geriatric population (Resnick & Pacala, 2012; Campanelli, 2012). As a reminder
for clinical practice, Fick and Semla (2012) propose the updated criteria could be easily
implemented into an electronic medical record and provide prompts and possibly
alternative interventions when a PIM has been identified.
The Beers Criteria has been examined extensively in research since its
development and found to be effective in identifying PIM and advising close monitoring
of certain medications (Gillespie et al, 2013). However, evidence supporting the
effectiveness of the Beers Criteria in consistently reducing ADR or decreasing cost or
mortality is lacking (Spinewine, Schmader, Barber, Hughes, Lapane, Swine, Hanlon,
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2007; Jano & Aparasu 2007; Resnick & Pacala, 2012; Pham & Dickman, 2007). The
Beers Criteria does not take into account geriatric patients in palliative care or hospice,
does not detect prescribing omissions, underuse of medications, drug to drug interactions,
inappropriate dosing of medications, or duplication of drug classes (Shahezwan et al,
2012: Barry et al, 2007; Gallagher et al, 2007; Fick & Semla, 2012).
STOPP Criteria
A newer physiological systems based explicit screening tool is the
STOPP/START Criteria, developed in Europe in 2003, and validated with a Delphi
consensus for use in 2006 (Gallagher et al, 2007). The STOPP/START Criteria is used to
detect PIM being prescribed and to identify PPO. Eighteen experts in Geriatric
Pharmacotherapy from Ireland and the United Kingdom participated in two rounds of the
Delphi validation process (Gallagher et al, 2009; Dalleur et al, 2012; Gallagher et al,
2007; Yayla, Bilge, Binen, Keskin; 2013). The criteria, last updated in 2006, are broken
down by body system, take into account specific patient information, and are separated
into a list of PIM to STOPP and a list of PPO to START. The STOPP/START Criteria
are supported by the European Union of Geriatric Medicine Society (EUGMS) and was
slated for an updated validated version in late 2012 or early 2013 (Marcum & Hanlon,
2012). The criteria is helpful in completing medication reviews because it considers the
patients diagnosis and past medical history, PIM, PPO, duplicate drug classes, duration of
treatment errors, and medications likely to cause a fall (Shahezwan et al, 2012; Gallagher
et al, 2009; Barry, Gallagher, Ryan, O’Mahony, 2007; Gallagher et al, 2007).
The STOPP Criteria contains 65 evidence based indicators for potentially
inappropriate prescribing with an explanation for why the medication could be
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inappropriate in a geriatric patient appearing next to each criteria (Gallagher et al, 2009;
Dalleur et al, 2012; Gallagher et al, 2007; Onatade, Auyeung, Scutt, Fernando, 2013).
The STOPP Criteria can be used as a medication screening tool effectively even without
a patient’s past medical history or other clinical information (Ryan et al, 2012). It is
believed to be comprehensive and time efficient (Gallagher et al, 2007). The STOPP
Criteria takes approximately three minutes per patient to use and could readily be
incorporated into an electronic medical system for easier application (Gallagher,
O’Connor, O’Mahony, 2011; Ryan et al, 2009; Gallagher et al, 2009; Dalleur et al, 2012).
START Criteria
The START Criteria contains 22 evidence based indicators for prescribing
omissions with an explanation for why the medication could be indicated in a geriatric
patient appearing next to each criteria (Gallagher et al, 2009; Dalleur et al, 2012). The
most effective method to apply this criteria as a medication screening tool is to have a
patient’s past medical history and other clinical information available (Ryan et al, 2012).
Physicians may be cautious to prescribe medications to geriatric patients out of fear
related to multiple co-morbidities, fear of polypharmacy, economic reasons, or ageism
(Cherubini, Corsonello, Lattanzio, 2012). However, this criteria has compiled a list of
medications that are indicated to prevent or treat disease and can be applied in one minute
(Cherubini, 2012; Beer, Hyde, Almeida, 2011; Gallagher, O’Connor, O’Mahony, 2011;
Ryan et al, 2009; Gallagher et al, 2009).
Review of current literature revealed the two most common prescription
omissions were Calcium and Vitamin D supplements in OP and high fall risk men and
women (Sloane, Gruber-Baldini, Zimmerman, Roth, Watson, Boustant, 2004; Rosen,
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Karter, Liu, Selby, Schneider, 2004; Kiebzak, Beinart, Perser, Ambrose, Siff, Heggeness,
2002; Trivedi, Doll, Khaw, 2003). Prevention and treatment of OP may be improved in
older adults with simple treatments like an appropriate single monthly dose of Calcium
and Vitamin D (Kiebazk, 2002; Trivedi, Doll, Khaw, 2003). Bisphosphonates are also
indicated for the treatment of OP and have been shown effective in preventing fractures
(Whitaker, Guo, Kehoe, Benson, 2012).
The goal for the use of a medication screening tool in practice is to allow
prescribers to use their expertise and clinical judgement in a timely manner as the tool
should be evidence-based, simple to use, and work well with an electronic medical record
(O’Mahony et al, 2008). There are several concerns expressed with both criteria.
Concerns with the Beers Criteria include poor organization, inefficiency, missing
medications and interactions, and duplicate medications and prescribing omissions are
not addressed (Ryan et al, 2009; O’Mahony, 2012; Cahir et al, 2010; O’Mahony et al,
2010; Shahezwan et al, 2012; Fisk & Semla, 2012; Barry et al, 2007; Campanelli, 2012).
Concerns with the STOPP/START Criteria include that existing research are reviews
rather than clinical studies, the last update was seven years ago, and there is a lack of
research conducted with the criteria in the United States (Bradley, Fahey, Cahir, Bennett,
O’Reilly, Parsons, and Hughes, 2012; Yayla et al; 2013; O’Mahony et al, 2010). The
Beers Criteria has been studied extensively in the U.S. and the STOPP/START Criteria
has been studied in a variety of settings across Europe; but minimally in the U.S. (Cahir
et al, 2010; O’Mahony, Gallagher, Byrne, Hamilton, Barry, O’Connor, Kennedy, 2010;
Vishwas, Harugeri, Parthasarathi, Ramesh, 2012; Ryan, O’Mahony, Kennedy, Weedle,
Byrne, 2009; Pham & Dickman, 2007; Shahezwan et al, 2012; Ramaswamy et al, 2010;
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Fick & Semla, 2012; Resnick & Pacala, 2012; Gallagher et al 2008; Lang Hasso, Belmin,
Payot, Baeyens, Vogt-Ferrier, Gallagher, O'Mahony, Michel, 2009, Cherubini et al, 2012;
Ubeda, Ferrandiz, Maicas, Gomez, Bonet, Peris, 2012, Windsant-van den Tweel,
Windsant-van den Tweel, Verduijn, Derijks, van Marum, 2012).
There are many similarities between the Beers Criteria and the STOPP/START
Criteria, therefore, studies have been conducted in Europe to compare the two criteria.
The Beer’s Criteria has a disadvantage in European studies versus the STOPP/START
Criteria because some of the medications that appear on the Beers Criteria are not
available in Europe (Yayla et al, 2013). Overlooking this disadvantage, European
research suggests STOPP Criteria may be more sensitive and possibly more effective
than the Beers Criteria at identifying PIM and preventing ADRs. This increased
sensitivity may be attributed to the 33 PIM that appear on the STOPP Criteria that are not
present on the Beers Criteria (Gallagher et al, 2007; Gallagher, O’Mahony, 2008;
Hamilton et al, 2011; O’Mahony et al, 2010; Ryan et al, 2009).
Hamilton and colleagues (2011) found in 151 potentially avoidable ADR that led
to hospitalization in Ireland, 94 were found in the STOPP Criteria compared to 34
identified by the Beers Criteria. Ryan and colleagues (2009) found in Irish primary care
that the Beers Criteria identified PIM in 18.3 percent of patients, STOPP Criteria
identified PIM in 21.4 percent, and START Criteria identified PPO in 22.7 percent of
patients. Gallagher and colleagues (2011) determined that appropriate prescribing is
significantly improved after correct and rigorous application of STOPP/START, even if
only applied one time. Gallagher and colleagues (2008) found a significant difference in
the detection of PIM. Hill-Taylor and colleagues (2013) conducted a systematic review
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and determined the STOPP/START Criteria may be more sensitive than the 2003 version
of the Beers Criteria.
The previous studies were conducted in European settings. Few studies have
examined the STOPP/START Criteria in the U.S., Brahmbhatt and colleagues (2013)
applied the STOPP/START Criteria in the U.S. and found a significant decrease in the
number of medications triggered as inappropriate after initial and follow-up application
of the criteria. With the limited research conducted in the U.S., especially in comparing
the STOPP/START Criteria and the Beers Criteria additional research needs to be
conducted in the U.S. to determine which criteria is more appropriate or effective in
minimizing inappropriate medications and ADRs.
Theoretical Framework
Inappropriate medications increase the likelihood of ADR. Adverse drug
reactions include a negative reaction to pharmacotherapy including confusion,
depression, constipation, falls, fractures, delirium, possible hospitalization, and mortality
(Cahir et al, 2010; Shahezwan, 2012; Hamilton, 2009; Brahmbhatt, Palla, Kossifologos,
Mitchell, and Lee, 2013; Pretorius et al, 2013). Potentially inappropriate medications
may be detected with a medication review (Hamilton, Gallagher, O’Mahony, 2009;
O’Sullivan, O’Mahony, Parsons, Murphy, Patterson, Byrne, 2013). A medication review
is a structured examination that involves identifying all current prescription, over-thecounter, and complementary medications an individual is taking in an attempt to agree
about their treatment, decrease cost, and prevent or minimize inappropriate medications
(NHS Cumbria Medicines Management Team, 2013; Pretorius et al, 2013).
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Medication reviews should be conducted when a patient is seen for the first time,
every six months or annually, when a new medication is prescribed, or when there is a
transition of care (Feinberg and Simonson, 2005, Barnsteiner, 2008; Pham & Dickman,
2007; Ryan 2012). More than 40 percent of PIM are present because medication reviews
were not conducted during a transition of care (Barnsteiner, 2008). Critical review of
medication lists in geriatric patients often results in change (Cockburn, 1997; Taziaux,
Franck, Ludovicy, Albert, 1996). Therefore, if a medication review tool is regularly
utilized to assess medication lists, some PIM may be discontinued and some PPO may be
initiated resulting in improved patient safety and decreased morbidity (Hamilton et al,
2009, O’Sullivan et al, 2013; Hill-Taylor, Sketris, Hayden, Byrne, O’Sullivan, Christie,
2013).
Patient safety is the goal of healthcare providers and the organizations in which
they function. Medication screening tools may be a simple and effective means to
promote and achieve the goal of increased patient safety by screening for PIM or PPO.
Effectiveness of a medication review depends on the environment, including how much
time the provider is able to spend with a patient, the thoroughness of the reported
medication list, and a familiarity with the patient’s medical and social history.
Scott’s Adaptation of Leavitt’s Diamond
Leavitt’s Diamond is an organization model created by Harold J. Leavitt in 1965
(Bloomsbury Business Library, 2007). Leavitt created a diamond shaped visual as a way
to understand the model that an organization exists within its environment and does not
experience change in isolation, but rather as change occurs to one part of the diamond it
will impact every other part (Bloomsbury Business Library, 2007).

15

In 1998, W. Richard

Scott, a sociology professor at Stanford University, adapted Leavitt’s original diamond.
The four corners of Scott’s adaptation of Leavitt’s diamond include 1) technology, 2)
participants, 3) social structure, and 4) goals (Wilson, 1995; Roberts, Hopp, Sorensen,
Benrimoj, Chen, Herborg, Williams, and Aslani, 2003). Scott’s adaptation of Leavitt’s
Diamond serves as the theoretical framework for this study.

Environment
Organization
(Roberts, Hopp,
Sorensen, Benrimoj,
Chen, Herborg,
Williams, and Aslani,
2003)

Technology

Goals

Participants

Conceptual and Operational Definitions
In Scott’s model the entire organization exists within an environment and all the
parts work together. The 1) technology refers not only to the computers and machines
used within the organization but also the protocols, guidelines, and resources that are
used to promote quality and achieve goals. The 2) participants are the people involved in
the organization. The 3) social structure is the culture or relationship the participants have
16

with the organization and could include the way participants interact with one another,
financial resources, the physical environment the organization exists within, etc. The 4)
goals are the outcomes the participants and organization are trying to achieve. The goals
of an organization must be the same for all participants for true success to be achieved.
The strength and success of the entire organization relies on the knowledge, skills, and
dedication of the participants.

Every part of the diamond affects the others and requires

the others to function (Wilson, 1995; Roberts et al, 2003).
The present study is examining the 1) technology corner, the 2) participants
corner, and the 3) social structure corner of the Scott’s model. The 1) technology for this
study is operationally defined as medication screening tools specifically, sections of the
Beers Criteria and the STOPP/START Criteria.

The 2) participants for this study are

patient medical records and the 3) social structure is the setting of a musculoskeletal
specialty practice.
Potentially inappropriate medications are those that pose a greater risk than
benefit for the patient (Shahezwan, 2012; Gallagher, Baeyens, Topinkova, Madlova,
Cherbuini, Gasperini, Cruze-Jentoft, Monero, Lang, Michel, O’Mahony, 2009; Gallagher,
Ryan, Byrne, Kennedy, O’Mahony, 2007; O’Mahony et al, 2008; Ramaswamy et al,
2010; Parsons, Johnston, Mathie, Baron, Machen, Amador, Goodman, 2012). This
encompasses polypharmacy, medication duplication, PPO, dosage errors, duration of
treatment errors, and prescribing cascades (Gallagher et al, 2007; Shahezwan et al, 2012).
Polypharmacy does not have a consensus definition in literature but many studies cite
five or more medications as a common occurance and the point at which patients become
more likely to experience an ADR (Pham & Dickman, 2007; Williams, 2002; Olsson,
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Runnamo, Engfeldt, 2011; Dovjak, 2012). For the purpose of this study, polypharmacy
means taking five or more medications (Kaufman, Kelly, Rosenberg, Anderson, Mitchell,
2002; Pham & Dickman, 2007). Medication duplication occurs when multiple drugs
from the same class are being taken. Dosage errors occur when a medication is being
taken at a dose with higher or lower than what is indicated for treatment. Duration of
treatment errors include a medication being taken for either too many or too few days.
Prescribing cascades include when a patient develops an unexpected side effect from one
medication that is mistaken as another disease process and requires treatment from
another medication (Rochon & Gurwitz, 1997). Potential medication omissions occur
when a medication indicated for treatment is not being taken (Cherubini et al, 2012).
In the U.S. the Beers Criteria has been used extensively to identify PIM in the
geriatric population. Currently there is not enough research evidence to make a
recommendation for prescribers in the U.S. to use the STOPP/START to identify PIM.
There is a need to apply both the STOPP/START and the Beers Criteria to the same
geriatric population in a U.S. setting to describe and compare their application. A
musculoskeletal specialty setting in the midwest was selected as an ideal setting due to
the ability to review the medical records of geriatric patients who suffer from chronic
conditions including OA, OP, falls, and fractures.
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Chapter Three: Methodology
Research Design
The research design for this study was a retrospective descriptive, comparative
design. A chart review was completed for the purpose of describing and comparing the
appropriateness of the Beers Criteria versus the STOPP/START Criteria in identifying
PIM or PPO in a U.S. setting.
Criteria Validity
The Beers Criteria content validity was established in 1991. Validity was
established using two rounds of Delphi consensus methodology with a panel of 13
experts. Most recently in 2012 the American Geriatric Society sponsored 11 experts to
update and revise the 2003 Beers Criteria (Marcum & Hanlon, 2012).
The STOPP/START Criteria’s content validity was established using two rounds
of Delphi consensus methodology in 2003 and 2006. A panel of 18 experts in geriatric
medicine, pharmacotherapy, old age psychiatry, and primary from Ireland and UK
collaborated to establish the final STOPP/START Criteria. The final STOPP Criteria
contains 65 of the original proposed 68 criteria and all 22 of the original START Criteria
(O’Mahony et al, 2009). The criteria has strong inter-rater reliability with a kappa
coefficient for STOPP 0.88 and START 0.90 among pharmacists and STOPP 0.75 and
START 0.68 among physicians (Ryan et al, 2009; Gallagher et al, 2009).
Setting
The setting of this study was a musculoskeletal specialty practice in the Midwest.
This setting offered a large volume of geriatric patients with risk for falls, fractures, and
musculoskeletal conditions including OA and OP.

19

Participants
The participants of this study were a convenient sample of patient medical records
from a musculoskeletal specialty practice. The sample size for this study was 60 medical
records.
Inclusion criteria included both males and females, of all races and ethnicities.
Participants were all 65 years of age or older, seen at the practice within a six month
period (December 2012-May 2013), and took at least one prescription medication on a
regular basis. Participants had at least one of the following diagnoses which are included
in the STOPP/START Criteria: OA, OP, gout, atrial fibrillation, hypertension, congestive
heart failure, peptic ulcer disease, gastrointestinal bleed, renal failure, Parkinson’s,
chronic pain, anxiety, depression, insomnia, or seasonal allergies. Exclusion criteria
included nursing home residents, because they are not living in the community and those
with diagnosed terminal illnesses because neither criteria is based on care of terminal
patients.
Data Collection
Data was collected in July 2013 from an electronic charting system. 1) Records
were accessed electronically by one researcher. 2) Selection began by electronically
identifying the records of patients seen during a six month period (December 2012-May
2013). 3) Records were then assessed for inclusion and exclusion criteria, specifically
past medical history, up to a convenient sample of 63 participants. Based on expected
attrition, three charts were added to the calculated sample size of 60. 4) The charts were
then coded one through 63 to ensure patient privacy. 5) Once 63 records were found that
met inclusion criteria, demographic data was collected as available (Appendix C). 5) The
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a. STOPP Central Nervous System & Psychotropic Drugs, b. STOPP Musculoskeletal
System Drugs, c. STOPP Drugs that Adversely Affect those Prone to Falls, and d.
STOPP Analgesic Drugs (Appendix A) were applied to each medical record. 6) The
START Musculoskeletal System Criteria (Appendix A) was applied to each medical
record. 7) The Beers Criteria PIM to avoid by therapeutic category a. Antihistamines, b.
Pain Medications, and PIM to avoid by disease/syndrome c. History of Falls or Fractures,
d. History of Gastric Ulcer and Duodenal Ulcers, e. Chronic Kidney Disease were applied
to each medical record. The application of each criteria to each individual medical record
was timed. 8) Confidentiality and privacy were ensured with a systematic approach, only
identifying the patients by one through 63, and keeping collected information locked.
Data Analysis
Data was analyzed on SPSS version 21.0 (IBM corp, 2012). The demographic
and past medical history characteristics of the sample were identified using descriptive
statistics reported as percentages, frequencies, means, and standard deviations. 1) Rate of
PIM identified by specific sections of the Beers Criteria (Appendix B) and specific
sections of the STOPP Criteria (Appendix A), 2) Rate of PPO identified by a specific
section of the START Criteria (Appendix A), 3) most common PIM or PPO drug classes
identified by each criteria, and those 4) identified with polypharmacy, and 5) length of
time for application of each criteria was also identified using descriptive were identified
using descriptive statistics reported as percentages, frequencies, means, and standard
deviations.
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Ethical Considerations
Approval from the Institutional Review Board at Cedarville University and the
musculoskeletal specialty practice was obtained in June 2013. Due to the nature of this
retrospective study design, the researcher had no contact with the individual patient, and
no patient harm was anticipated. An ethical consideration was protecting patient’s health
information. To protect patient’s privacy, the only data collected was information that
appeared on the approved demographic collection tool and the two criteria. No patient
identifiers were collected, patients were identified from one to 63.
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Chapter 4: Results
Sample Characteristics
A total of 63 medical records were identified and included in this retrospective
descriptive, comparative chart review. Table one summarizes the demographic
characteristics of the sample. The mean age of patients was 74 + 7.2 years, 95.2% were
Caucasian, and 60.3% were females. The total number of medications prescribed was
468, with a range of 1-25 medications per patient and a mean of 7.43 medications per
patient. The most common chronic disease identified was OA in 98.4% of the sample.
Table 1
Demographic Data
Characteristic
Male
Age
Race
Caucasian
African American
Asian/Pacific Islander
Insurance
Private
Medicare
Medicare with Secondary Carrier
Hospitalizations in the last year

No. (%)

Range

74.68(+7.2)

65-95

25 (39.7)

60 (95.2)
2 (3.2)
1 (1.6)
8 (12.7)
26 (41.3)
29 (46)
4 (6.3)

Falls in the last 3 months
Most common Chronic Diseases
Osteoarthritis
Hypertension
Hyperlipidemia
Hypothyroidism
Depression
Osteoporosis

Mean (SD)

3 (4.8)
62 (98.4)
49 (77.8)
27 (42.9)
12 (19)
11 (17.5)
10 (15.9)
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Rates of PIM
Beers Criteria results. Table two summarizes PIM identified by sections of both
the Beers and the STOPP Criteria. After applying the Beers Criteria, a total of 32 PIM
were identified in 39.7% of medical records, with 72% of PIM being prescribed to
females. Twenty two (68.8%) medical records with PIM had one medication identified
and five (31.3%) medical records with PIM had two medications identified.
STOPP Criteria results. After applying the STOPP Criteria a total of 67 PIM
were identified in 58.7% of medical records. Females were prescribed 67.6% of PIM.
Seventeen (25.4%) medical records with PIM identified one medication, 13 (38.8%)
medical records with PIM identified two medications, five (22.4%) medical records with
PIM identified three medications, one (6%) medical record with PIM identified four
medications, and one (7.5%) medical record with PIM identified five medications.
Table 2
PIM Identified by the Beers & STOPP Criteria
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STOPP Criteria
No. (%)
18 (25.4)
13 (38.8)
5 (22.4)
1 (6.0)
1 (7.5)
67

No. Males with PIM

7 (28)

12 (32.4)

No. Females with PIM

18 (39.7)

25 (67.6)

Total no. of individuals with
PIM identified

25 (39.7)

37 (58.7)

No. of PIM
1
2
3
4
5
Total no. of PIM

Beers Criteria
No. (%)
22 (68.8)
5 (31.3)
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Rates of PPO
START Criteria results. Table three summarizes the PPO identified by the
musculoskeletal section of the START Criteria. After applying the START Criteria a
total of 16 PPO were identified in 11 individuals, 63.6% of PIM were prescribed to
females. Six (37.5%) medical records with PPO had one medication identified, five
(62.5) medical records with PPO had two medications identified. Omission of Calcium
supplements accounted for 37.5% of all PPO and omission of Vitamin D accounted for
31.3% of all PPO (Table 3). The mean age of those identified with a PPO was 78.5 years
while the mean age of those without PPO identified was 73.9 years.
Table 3
PPO identified by START Criteria
START Criteria
No. of PPO

No. (%)

1
2

6 (37.5)
5 (62.5)

Total no. of PPO

16

No. of Males with PPO

4 (36.4)

No. of Females with PPO

7 (63.3)

Total no. of individuals with PPO

11 (17.5)

PIM and PPO Identified by Class
PIM classes identified by Beers Criteria. Table four summarizes the most
frequent classes of PIM identified by sections of the Beers Criteria. The prescription of
NSAIDS, excluding aspirin (ASA), accounted for 68.8% of PIM identified by the criteria,
specifically the section independent of diagnosis. The prescription of benzodiazepines in
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patients with a history of falls accounted for 3.1% of PIM identified, and was the only
medication class identified by the Beers Criteria section that considers diagnosis.
Table 4
PIM Classes: Beers Criteria
Medication

Total No. (%)

Drug Class (Independent of Diagnosis)
First Generation Antihistamines
NSAID (excluding ASA)
Skeletal Muscle Relaxants
Drug Class (Considering Diagnosis)
Benzodiazepines with history of fall
Total no. of PIM

6 (18.8)
22 (68.8)
3 (9.4)
1 (3.1)
32

PIM classes identified by STOPP Criteria. Table five summarizes the most
frequent classes of PIM identified by the applied sections of the STOPP Criteria. The
long-term use of NSAIDs to treat OA accounted for 49.3% of PIM and long-term opiate
use to treat mild to moderate pain accounted for 26.9% of PIM identified by the STOPP
Criteria. Some medical records triggered PIM in multiple sections of the STOPP Criteria
for several medication classes including, NSAIDs, benzodiazepines, opiates, and first
generation antihistamines. Those medications were only counted as one PIM, because
the different sections identified one PIM, several different times (Table 5*). There were,
however, several medical records that had more than one medication from a drug class
listed, including NSAIDs and opiates, and those medications were counted separately and
included in the total PIM.
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Table 5
PIM Classes: STOPP Criteria
Medication

Total No. (%)

CNS & Musculoskeletal System
Long-term Benzodiazepines
st
Prolonged use of 1 Generation Antihistamines

8 (11.9)
6 (8.9)

Musculoskeletal System
NSAID with moderate-severe Hypertension
NSAID with Heart Failure
Long-term NSAID use to treat OA
Long-term Corticosteroid use to treat OA or Rheumatoid
Arthritis (RA)

3 (4.5)
1 (1.5)
29 (43.3)
2 (2.9)

Drugs that Adversely Affect Fallers
Benzodiazepines
st
1 Generation Antihistamines

1*
1*

Analgesic Drugs
Long-term Opiates to treat mild-moderate pain

18 (26.9)

Total no. of PIM
*not included

67

in total count of PIM , already identified & counted as PIM in a previous section of criteria

PPO classes identified by START Criteria. Table six summarizes the most
frequent classes of PPO identified by the START Criteria musculoskeletal section. The
most common potential prescription omissions identified were Calcium and Vitamin D.
Omission of Calcium supplements accounted for 37.5% of all PPO and omission of
Vitamin D accounted for 31.3% of all PPO.
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Table 6
PPO Classes: START Criteria
Medication

START Criteria

Musculoskeletal System
DMARD with RA
Bisphosphonates
Calcium Supplement
Vitamin D Supplement

1 (6.2)
4 (25)
6 (37.5)
5 (31.3)

Total no. of PPO

16

Polypharmacy
Table seven summarizes the percentage of the sample with polypharmacy.
Polypharmacy was identified in 73.02% of medical records. Patients were taking an
average of 7.4 medications.

Table eight summarizes the average number of medications

per age range. The age range between 85-89 years had the highest average number of
mediations per patient (9.8); however, there were only four medical records included in
this age range. The largest number of medical records, (25 records, 37.3%) were in the
age range of 70-74 years of age.
Table 7
Patients Experiencing Polypharmacy
Characteristic

No. (%)

Total no. of Drugs Prescribed

468

Mean no. of Drugs Prescribed per Patient
No. of patients with Polypharmacy (>5 Drugs)
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SD

Range

7.4

+4.7

1-25

46 (73)

4.4

Table 8
Mean Medications Prescribed per Age Range

Length of Time
Table nine summarizes the length of time for the application of each criteria. The
sections of the Beers Criteria that were applied took a mean time of 17.38 seconds a
medical record. The sections of the STOPP Criteria that were applied took a mean time of
20.15 seconds a medical record. The section of the START Criteria applied took a mean
time of 4.02 seconds a medical record.
Table 9
Length of Time for Application per Criteria
Beers Criteria

STOPP Criteria

START Criteria

Variable

Mean

SD

Range

Mean

SD

Range

Mean

SD

Range

Mean time
in seconds

17.4

+7.1

8-46

20.2

+8.9

8-53

4

+1.7

2-10
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Chapter 5: Summary
Discussion Overview
This study showed that the use of medication screening tools, specifically sections
of both the Beers and STOPP/START Criteria, identified PIM and PPOs with a
retrospective chart review. There is little to no research conducted with the application of
only selected sections of both criteria, specifically in a musculoskeletal practice,
therefore, the results of this study are somewhat unique. Several European studies
conducted in a variety of settings have compared the application of the entire Beers and
STOPP/START Criteria and the rate of PIM. Due to the similar content of other studies
and the present study, results can be compared while being mindful the differences in
methodology and design.
Discussion of Sample Characteristics
Considering the setting for data collection, it was anticipated that there would be a
high incidence of musculoskeletal conditions including OA, OP, falls, and fractures.
There was a high incidence, as expected, of OA with all but one medical record having a
documented past medical history of OA. It was surprising there was not a higher
incidence of OP, with only 15.9% of the medical records reported OP in the past medical
history. The reason for this low incidence is unknown. Additionally, the low incidence
of hospitalizations or falls reported in patients was surprising. Hospitalizations have been
linked as a possible ADR caused by PIM (Yayla et al, 2013). The ability to detect PIM
may have been hindered with the low rates of reported hospitalizations and falls.
sections of criteria related to patients with a history of falls were not applied to the
medical records that did not report a recent fall. If a patient had a fall that was not
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The

documented or reported, they could be at an unknown risk for PIM that is not being
assessed.
Discussion of Rates of PIM
Based on review of current literature it was anticipated the STOPP Criteria would
identify more PIM than the Beers Criteria. Ryan and colleagues (2009) reported in a
study conducted in an Irish primary care setting that the Beers Criteria identified PIM in
18.3% of patients and the STOPP Criteria identified PIM in 21.4% of patients. Gallagher
and O’Mahony (2008) reported in an Irish acute care setting that the Beers Criteria
identified PIM in 25% of patients while the STOPP Criteria identified PIM in 35% of
patients. Ubeda and colleagues (2012) conducted a study in long-term care facilities in
Spain comparing the Beers and STOPP/START Criteria and reported the Beers Criteria
identified PIM in 25% while STOPP identified PIM in 48% of patients. A study done by
Vishwas and colleagues (2012) reported different results from previously mentioned
studies stating the Beers Criteria identified PIM in 24.6% of patients and STOPP only
identified PIM in 13.3%. The present study results show the rate of PIM identified in a
musculoskeletal specialty practice in the Midwest applying specific sections of the Beers
Criteria is 39.7% and specific sections of the STOPP Criteria is 58.7%.
The Beers and STOPP criteria have many similar PIM recommendations;
however, there are several differences that may impact the number of PIM identified by
each. The organization of the criteria may impact the number of PIM identified. The
STOPP Criteria is organized by body system and considers specific patient clinical data,
duplicate drug classes, and PPO while the Beers Criteria has 3 lists of medications to 1)
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avoid considering diagnosis, 2) avoid independent of diagnosis, 3) use with caution and
does not address PPO.
Both criteria overall identified NSAIDs, antihistamines, and benzodiazepines as
PIM. The Beers Criteria does not identify Aspirin >325mg daily to be to a potentially
inappropriate NSAID or opiates to be PIM in the sections applied. The STOPP Criteria
does not consider skeletal muscle relaxants as a PIM in the sections applied. A benefit to
applying the STOPP Criteria is the patient specific information in each recommendation;
however, this does bring some difficulty in a retrospective study. One difficulty is in
determining if OA being treated with NSAIDS is mild to moderate. Based on review of
current literature it was anticipated the STOPP Criteria would identify more PIM than the
Beers Criteria. Ryan and colleagues (2009) reported in a study conducted in an Irish
primary care setting that the Beers Criteria identified PIM in 18.3% of patients and the
STOPP Criteria identified PIM in 21.4% of patients. The results of the present study
show the rate of PIM identified in a musculoskeletal specialty practice in the Midwest
applying specific sections of the Beers Criteria is 39.7% and using sections of the STOPP
Criteria is 58.7%. These results are similar to the previously mentioned results of other
studies in that the rate of PIM was higher with application of the STOPP Criteria than
with the Beers Criteria.
Discussion of rates of PPO
One benefit of applying the STOPP/START Criteria is the recognition of PPO by
START, which the Beers Criteria does not consider. Ryan and colleagues (2009)
reported in a study conducted in an Irish primary care setting that PPOs were identified in
22.7% of patients with a significantly higher incidence in females. The results of the
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present study showed the rate of PPO identified in a musculoskeletal specialty practice in
the Midwest using a section of the START Criteria was 17.5% and the incidence was
higher in females (63.3%). This result could be due, at least partially, because there were
more females than males in the total sample.
Discussion of PIM and PPO Identified by Class
Discussion of PIM classes identified by Beers Criteria. Based on review of
current literature Ryan and colleagues (2009) found that with the Beers Criteria, the
identification of benzodiazepines accounted for 31.9% of PIM. Ubeda and colleagues
(2012) reported the two most commonly identified classes of PIM include NSAIDs and
benzodiazepines. According to the present study results the most common medication
classes identified by the Beers Criteria were NSAIDs (68.8%).
Discussion of PIM classes identified by STOPP Criteria. Based on review of
current literature and basic knowledge about the musculoskeletal setting, the most
anticipated classes of PIM included NSAIDs, opiates, and benzodiazepines. Dalleur and
colleagues (2012) reported two of the most common PIM classes identified by the
STOPP Criteria were benzodiazepines and opiates. In an Australian hospital setting
Shahezwan and colleagues (2012) reported the most common PIM identified by the
STOPP criteria were long-term opiates and benzodiazepines prescribed to elderly patients
with a history of falls. Cahir and colleagues (2010) reported that the second and third
most frequently reported PIM classes were, in order, NSAIDS for > 3 months and
benzodiazepines. According to the present study results the most common medication
classes identified by the STOPP Criteria were long-term NSAID use to treat OA (43.3%),
long-term opiates (26.9%), and long-term benzodiazepines (11.9%).
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Long-term NSAID use may be associated with gastrointestinal problems, heart
failure exacerbation, and chronic renal failure (Cahir et al, 2013). Benzodiazepine use in
the geriatric population is associated with increased risk for falls, fractures, respiratory
depression, impaired cognitive function, drowsiness, and dependence (Cahir et al, 2010;
Shahezwan et al, 2012; Berryman et al, 2012). Opiate use in the geriatric population can
cause drowsiness, respiratory depression, hypotension, impaired balance leading to
increased risk for falls and fractures (Shahezwan et al, 2012).
Discussion of PPO classes identified by START Criteria. Dalleur and
colleagues (2012) and Ubeda and colleagues (2012) found that the most common PPO in
hospitalized elderly patients were the underuse of Calcium and Vitamin D
supplementation. According to the present study the most common PPO classes
identified by the START Criteria were Calcium supplements (37.5%) and Vitamin D
supplements (31.3%). As previously mentioned, there was a low incidence of patients
with OP in this study. This low incidence might negatively affect the identification of the
PPO of bisphosphonates. This could negatively impact patient outcomes considering,
Dalleur and colleagues (2012) reported that fall-induced osteoporotic fractures were the
most common hospital admission diagnosis related to inappropriate prescribing.
Discussion of Polypharmacy
Due to the advanced age of the sample and multiple chronic diseases it was
anticipated that a large number of patients would have polypharmacy. According to the
present study 46 patients (73%) had polypharmacy. The mean number of drugs
prescribed per patient was 7.4 medications with a range of 1-25 medications. When
considering the average number of medications per age range, it was anticipated that as
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age increased, the average number of medications would also increase as was reported in
a study conducted by Ryan and colleagues (2009). In this study, however, this was not
the case. This unexpected finding could be a result of the unequal number of medical
records in each age range (Table 8).
Discussion of Application Length of Time
Only sections of each criteria were applied, for this reason it was difficult to
predict the length of time for application of each criteria. According to the present study
the sections of the Beers Criteria took a mean time of 17.4 seconds to apply to a medical
record, 2.8 seconds less on average than the sections of the STOPP Criteria. The section
of the START Criteria took an average of 4 seconds per medical record. In current
literature, no studies were found that compared the application time of the Beers Criteria
and the STOPP/START Criteria in their entirety or sections. Literature states that an
individual familiar with the STOPP Criteria can apply it in its entirety in 3 minutes and
the START criteria within 1 minute. There is a short learning curve while one becomes
familiar with the criteria (Gallagher et al, 2011).
Limitations
There were several limitations to this study. There is a lack of generalizability of
results related to the small sample size and application in one specialty care practice in
the Midwest. Due to the retrospective design of the study there was a limited ability to
consider prescribers opinions and clinical judgement. Medications could have been
identified as PIM that were clinically appropriate. Application of only particular
sections, rather than the entire STOPP/START Criteria or Beers Criteria is a potential
limitation that may affect validity and reliability of the criteria. However, based on the
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specialty practice where data was collected, a selection of criteria sections that match the
specialty practice focus seemed appropriate for study. The low incidence of documented
hospital stays, recent falls, kidney function, and history of ulcers resulted in certain
sections of both criteria not being applicable to medical records. This may cause a false
decrease in the number of PIM identified by each criteria.
Implications for Practice
Descriptive statistics confirmed that sections of the STOPP Criteria identified
more PIM than sections of the Beers Criteria in the same sample. However, at least in the
sections applied the Beers Criteria may be faster to apply to a medical record. The
limitation of only applying sections of each criteria impacts the implications for practice
because a provider would likely apply the entire criteria to a medical record.
Recommendations for Future Research
Future research recommendations relating to the study of the Beers and
STOPP/START Criteria include studies with larger sample sizes, a primary care setting
in the U.S., and the application of both criteria in their entirety. A different study design
should be conducted to assist in the application of the criteria in conjunction with clinical
judgement to see how the criteria function in practice. Both criteria need regular updates
to remain relevant for future study.
Conclusion
In conclusion, the problem of avoiding PIM and preventing potential ADR in the
geriatric population is complex. However, prevention of PIM and potential ADR may be
achieved with a medication screening tool. Medication screening tools can assist with
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education about PIM and a reminder to regularly evaluate medications prescribed to the
geriatric population.
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Appendix A
STOPP Criteria: (O’Mahony et al, 2010)
Screening Tool of Older People’s potentially inappropriate Prescriptions
The following drug prescriptions are potentially inappropriate in persons aged 65 years
of age.
A. Central Nervous System & Psychotropic Drugs
1.Tricyclic antidepressants (TCAs) with dementia
2. TCAs with glaucoma
3. TCAs with cardiac conductive abnormalities
4. TCAs with constipation
5. TCAs with an opiate or calcium channel blocker
6. TCAs with prostatism or prior history of urinary retention
7. Long-term (>1month) long acting benzodiazepines
8. Long-term (>1month) neuroleptics as long-term hypnotics
9. Long-term (>1month) neuroleptics in those with Parkinsons
10. Phenothiazines in patients with epilepsy
11. Anticholinergics to treat extrapyramidal side effects of neuroleptic
medications
12. Selective serotonin re-uptake inhibitors (SSRIs) with a history of clinically
significant hyponatraemia
13. Prolonged use (>1week) of first generation antihistamines
B. Musculoskeletal System Drugs
1. Non-steroidal anti-inflammatory drug (NSAID) with history of peptic ulcer
disease or gastrointestinal bleeding, unless with concurrent histamine H2
receptor antagonist, PPI, or misoprostol
2. NSAID with moderate-severe hypertension (moderate: 160/100-179/100;
severe 180/110)
3. NSAID with heart failure
4. Long-term use of NSAID (>3months) for symptoms relief of mild osteoarthritis
5. Warfarin and NSAID together
6. NSAID with chronic renal failure (Serum Cr >150, GFR 20-50 ml/min)
7. Long term corticosteroid use (>3months) as monothearpy for rheumatoid
arthritis or osteoarthritis
8. Long term NSAID or colchicine for chronic treatment of gout where there is no
contraindication to allopurinol.
C. Drugs that Adversely Affect Fallers
1. Benzodiazepines
2. Neuroleptic drugs
3. First-generation antihistamines
4. Vasodilator drugs with persistent postural hypotension (recurrent >20mmHg
drop in systolic BP)
5. Long-term opiates in those with recurrent falls
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D. Analgesic Drugs
1. Use of long-term powerful opiates as first line therapy for mild to moderate
pain.
2. Regular opiates for >2weeks in those with chronic constipation without
concurrent use of laxatives
3. Long-term opiates in those with dementia unless indicated for palliative care or
management of moderate-severe chronic pain syndrome
START Criteria:
Screening Tool to Alert doctors to Right i.e. appropriate, indicated Treatment.
These medications should be considered for people 65 years of age with the following
conditions, where no contraindication to prescription exists.
A. Musculoskeletal System Drugs
1. Disease-modifying antirheumatic drug with active moderate-severe rheumatoid
disease lasting >12 weeks.
2. Bisphosphonates in patients taking maintenance corticosteroid therapy
3. Calcium supplement in patients with known osteoporosis (previous fragility
fracture, acquired dorsal kyphosis)
4.Vitamin D in patients with known osteoporosis (previous fragility fracture,
acquired dorsal kyphosis)
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Appendix B
Beer’s Criteria (American Geriatric Society, 2012)
Organ System/Therapeutic Category/Drug(s)-Independent of Diagnosis
First Generation antihistamines (as a single agent or part of combination products)
-Brompheniramine
-Carbinoxamine
-Chlorpheniramine
-Clemastine
-Cyproheptadine
-Dexbrompheniramine
-Dexchlorpheniramine
-Diphenhydramine (oral)
-Doxylamine
-Hydroxyzine
-Promethazine
-Triprolidine
Pain Medications
Meperidine
Non-COX-selective NSAIDs, oral
-Aspirin >325mg/day
-Diclofenac (oral)
-Diflunisal
-Etodolac
-Fenoprofen
-Ibuprofen
-Ketoprofen
-Meclofenamate
-Mefenamic acid
-Meloxicam
-Nabumetone
-Naproxen
-Oxaprozin
-Piroxicam
-Sulindac
-Tolmetin
Indomethacin
Ketorolac (includes parenteral)
Pentazocine
Skeletal Muscle Relaxants
-Carisoprodol
-Chlorzoxazone
-Cyclobenzaprine
-Metaxalone
-Methocarbamol
-Orphenadrine
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Disease or Syndrome; Drugs-Considering Diagnosis
History of falls or fractures
Anticonvulsants
Antipsychotics
Benzodiazepines
Non-Benzodiazepine hypnotics
-Eszopiclone
-Zaleplon
-Zolpidem
TCAs/SSRIs
History of gastric or duodenal ulcers
-Aspirin (>325mg/)
-Non-COX-2 selective NSAIDs
Chronic kidney disease sages IV and V
-NAIDs
-Triamterene (alone or in combination)
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Appendix C
Demographic Data Collection Tool
Patient Identifier #: 1-63
Age:
Gender:
Race/Ethnicity:
Allergies:
Insurance provider:
Past Medical History (exclude terminally ill; include those with OP, OA, rheumatoid arthritis
(RA), gout, atrial fibrillation, hypertension, congestive heart failure, peptic ulcer disease,
gastrointestinal bleed, renal failure, chronic pain, Parkinson’s, anxiety, depression, insomnia, or
seasonal allergies):
Heart rate:
BP: (no hypertension, moderate hypertension-160-179/100, severe hypertension-180/110)
Hospitalizations in last year:
History of falls in last 3 months:
Current Medications (including prescription and OTC/supplements):

